{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:47:17Z","timestamp":1778626037062,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1053\/j.seminhematol.2005.12.008","type":"journal-article","created":{"date-parts":[[2006,3,19]],"date-time":"2006-03-19T21:09:49Z","timestamp":1142802589000},"page":"S22-S26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"S2","title":["Role of Single-Agent Purine Analogues in Therapy of Peripheral T-Cell Lymphomas"],"prefix":"10.1053","volume":"43","author":[{"given":"Claire E.","family":"Dearden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2005.12.008_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma)","volume":"13","author":"Rudiger","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib2","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","article-title":"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia","volume":"78","author":"Matutes","year":"1991","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib3","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2141.2001.02794.x","article-title":"Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma","volume":"113","author":"Matutes","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2141.1998.00977.x","article-title":"Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais d\u2019Hematologie Cellulaire","volume":"103","author":"Garand","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib5","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood.V95.10.3219","article-title":"Chronic neutropenia mediated by fas ligand","volume":"95","author":"Liu","year":"2000","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib6","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/S0140-6736(98)09460-4","article-title":"Human T-lymphotropic virus type I infection","volume":"353","author":"Manns","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.7326\/0003-4819-100-4-543","article-title":"NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia\/lymphoma virus","volume":"100","author":"Broder","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0165-4608(99)00151-X","article-title":"Chromosome abnormalities in peripheral T-cell lymphoma","volume":"117","author":"Lepretre","year":"2000","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib9","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(72)92345-8","article-title":"Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity","volume":"2","author":"Giblett","year":"1972","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib10","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/978-1-4684-5104-7_82","article-title":"Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A)","volume":"195","author":"Yu","year":"1986","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1600-0609.1984.tb02167.x","article-title":"Effectiveness of pentostatin (2\u2032-deoxycoformycin) in refractory lymphoid neoplasms","volume":"32","author":"Spiers","year":"1984","journal-title":"Scand J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1600-0609.1985.tb00744.x","article-title":"T-cell chronic lymphocytic leukaemia","volume":"34","author":"Spiers","year":"1985","journal-title":"Scand J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib13","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1023\/A:1008377724139","article-title":"Pentostatin in T-cell malignancies\u2014A phase II trial of the EORTC","volume":"10","author":"Ho","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.1986.tb07499.x","article-title":"Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukaemia","volume":"63","author":"el\u2019Agnaf","year":"1986","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jnci\/85.8.658","article-title":"Pentostatin in prolymphocytic leukemia","volume":"85","author":"Dohner","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib16","first-page":"37","article-title":"Pentostatin treatment of cutaneous T-cell lymphoma","volume":"14","author":"Dearden","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/bjc.1991.423","article-title":"Deoxycoformycin in the treatment of mature T-cell leukaemias","volume":"64","author":"Dearden","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib18","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V84.3.733.733","article-title":"2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders","volume":"84","author":"O\u2019Brien","year":"1994","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s002770050368","article-title":"Treatment of prolymphocytic leukemia with cladribine","volume":"76","author":"Lorand-Metze","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1600-0609.1997.tb01409.x","article-title":"2-Chlorodeoxyadenosine in the treatment of relapsed\/refractory chronic lymphoproliferative disorders","volume":"58","author":"Rondelli","year":"1997","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib23","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/BF02986621","article-title":"Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma","volume":"77","author":"Tobinai","year":"2003","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2169\/internalmedicine.37.411","article-title":"Adult T-cell leukemia-lymphoma successfully treated with 2-chlorodeoxyadenosine","volume":"37","author":"Uike","year":"1998","journal-title":"Intern Med"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s002770050244","article-title":"Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia using 2-chlorodeoxyadenosine","volume":"73","author":"Sallah","year":"1996","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10428199409049659","article-title":"Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues","volume":"14","author":"Witzig","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib27","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0002-9343(91)90546-A","article-title":"Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia","volume":"90","author":"Kantarjian","year":"1991","journal-title":"Am J Med"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/bjc.1991.253","article-title":"Fludarabine phosphate for the treatment of low grade lymphoid malignancy","volume":"64","author":"Whelan","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib29","first-page":"162","article-title":"Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine","volume":"24","author":"Weidmann","year":"2001","journal-title":"Onkologie"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib30","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1046\/j.1365-2141.2001.02795.x","article-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin\u2019s lymphoma","volume":"113","author":"Dumontet","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib31","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib32","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib33","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib34","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib35","first-page":"404a","article-title":"Phase II Evaluation of gemcitabine as a single agent for cutaneous T-cell lymphoma","volume":"102","author":"Talpur","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib36","first-page":"639a","article-title":"Phase II study of compound GW506U78 (AraG) for patients with indolent B-cell or peripheral T-cell lymphoma previously treatment with chemotherapy","volume":"102","author":"Goy","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib37","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib38","first-page":"394","article-title":"Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma","volume":"5","author":"Dillman","year":"1986","journal-title":"J Biol Response Mod"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib39","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","article-title":"Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody","volume":"87","author":"Knox","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib40","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood.V80.3.587.587","article-title":"2-Chlorodeoxyadenosine","volume":"80","author":"Saven","year":"1992","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib41","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1182\/blood.V87.3.906.bloodjournal873906","article-title":"Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma","volume":"87","author":"Kuzel","year":"1996","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/10428199709109162","article-title":"2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders","volume":"26","author":"Kong","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1023\/A:1008273131598","article-title":"Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia","volume":"9","author":"Betticher","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib44","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1053\/j.seminhematol.2005.12.008_bib45","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.1992.10.5.790","article-title":"Phase II trial of fludarabine phosphate in lymphoma","volume":"10","author":"Redman","year":"1992","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196305002659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196305002659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:16:46Z","timestamp":1758521806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196305002659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":45,"alternative-id":["S0037196305002659"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.12.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Single-Agent Purine Analogues in Therapy of Peripheral T-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2005.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}